A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination with Azacitidine in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Protocol: 
AAAR1077
Phase: 
I

A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination with Azacitidine in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

The purpose of this study is to evaluate the safety of venetoclax in
combination with azacitidine compared to azacitidine alone in subjects with
previously untreated higher-risk MDS.

The study will also look at how well the study drugs work and how much of
the
study drug is in your body at different times.

Are you Eligible? (Inclusion Criteria)

1) Subject must be at least 18 years of age.

2) Subject must have received no prior therapy for MDS

3) Subjects must be in good physical health. This means that the patient
should be capable of all self-care, even if they are unable to carry out any
work activities, and should be up and about more than half of waking hours.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States